Pharmacological characterization of [3H]-prostaglandin E2 binding to the cloned human EP4 prostanoid receptor

British Journal of Pharmacology

Volumn 130, Issue 8, 2000, Pages 1919-1926

  Davis, T L ^a   Sharif, N A ^a  

^a ALCON RESEARCH LTD   (United States)

Author keywords

Ligand binding; Prostanoids

Indexed keywords

15 METHOXY 17 (2 FURANYL) 18,19,20 TRINOR PROSTAGLANDIN F2 ALPHA; 17 (5 METHYL 2 FURANYL) 18,19,20 PROSTAGLANDIN F2 ALPHA; 24615; 24620; 3 BENZYL 5 (6 CARBOXYHEXYL) 1 (2 CYCLOHEXYL 2 HYDROXYETHYLAMINO)HYDANTOIN; 6 ISOPROPOXY 9 OXO 2 XANTHENECARBOXYLIC ACID; 6556; 6598; 7 [3 [(4 PHENYLSEMICARBAZIDO)METHYL] 7 OXABICYCLO[2.2.1]HEPT 2 YL] 5 HEPTENOIC ACID; 7 [5 (4 BIPHENYLYLMETHOXY) 2 MORPHOLINO 3 OXOCYCLOPENTYL] 4 HEPTENOIC ACID; 9BETA CHLORO 15 CYCLOHEXYL 9 DEOXY 16,17,18,19,20 PENTANOR 3 OXAPROSTAGLANDIN F2 ALPHA; 9BETA CHLORO 15 CYCLOHEXYL 9 DEOXY 16,17,18,19,20 PENTANORPROSTAGLANDIN F2 ALPHA; AH 22921X; AL 6556; AL 6598; BWA 245C; CLOPROSTENOL; ENPROSTIL; FLUPROSTENOL; ILOPROST; LATANOPROST; MISOPROSTOL; PHXA 85; PROSTAGLANDIN F2 ALPHA DERIVATIVE; PROSTANOID; PROSTANOID RECEPTOR; RECEPTOR SUBTYPE; RS 93520; S 1033; SC 19920; SQ 27986; SULPROSTONE; TRAVOPROST; UNCLASSIFIED DRUG; UNINDEXED DRUG;

ARTICLE; BINDING AFFINITY; BINDING SITE; CHEMICAL STRUCTURE; DRUG RECEPTOR BINDING; EMBRYO; HUMAN; HUMAN CELL; KIDNEY CELL; LIGAND BINDING; MOLECULAR CLONING; PRIORITY JOURNAL;

EID: 0033845789     PISSN: 00071188     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.bjp.0703525     Document Type: Article

References (39)

1. 2 protects cultured cortical neurons against N-methyl-D-aspartare receptor -mediated glutamate cytotoxicity
2. Prostaglandin F(2α) receptors in the human trabecular meshwork, Invest
3. 4 in the nuclear envelope
4. The ocular effects of prostaglandin and the therapeutic potential of a new PGF(2α) analog, PhXA41 (latanoprost) for glaucoma management
5. 2 prostanoid receptor subtypes
6. Nonlinear regression using spreadsheets
7. Cyclopentane heptan(ene)oic acid, 2-hetero-arylalkenyl derivatives as therapeutic agents. International Patent Application, WO 97/31895
8. 2) and PGF(2α) receptors and their functions during development
9. 50) of an enzymatic reaction
10. A novel inhibitory prostanoid receptor in piglet saphenous vein
11. VIII. International union of pharmacology classification of prostanoid receptors: Properties, distribution, and structure of the receptors and their subtypes
12. 4 prostaglandin receptors coupled positively to adenylyl cyclase in Chinese hamster ovary cells: Pharmacological characterization
13. 2- and IP-prostaglandin receptors in human ocular and other cell-types
14. Quantitative autoradiographic visualization and pharmacology of FP-prostaglandin receptors in human eyes using the novel phosphorimaging technology
15. 1 is mediated by receptor-coupled adenylyl cyclase in human anterior segments
16. Prostaglandin F(2α) increases uveoscleral outflow in the cynomolgus monkey
17. 2 production meditates the in vitro inhibitory effect of human immunodeficiency virus P24 immunosuppressive heptapeptide Ch7
18. Molecular aspects of the structures and functions of the prostanoid E receptors
19. Ligand binding specificities of the eight types and subtypes of the mouse prostanoid receptors expressed in Chinese hamster ovary cells
20. Prostaglandin increase proMMP-1 and proMMP-3 secretion by human ciliary smooth muscle cells
21. Pharmacological studies on prostanoid receptors in the rabbit isolated saphenous vein: A comparison with rabbit isolated ear artery
22. 4 receptors expressed with Semliki Forest virus
23. 2 binding sites in the human eye
24. A practical computer based approach to the analysis of radioligand binding experiments
25. 2 inhibits lipopolysaccharide-induced tumour necrosis factor-alpha generation
26. 4 receptors positively coupled to adenylate cyclase
27. 4 in human kidney
28. 4 subtype: Differential regulation in monocytoid and lymphoid lineage cells by phorbol ester
29. 4, and FP receptors in human ciliary epithelial and ciliary muscle cells
30. 4 triggers remodelling of the cardiovascular system at birth
31. 4, differ in desensitization and sensitivity to the metabolic inactivation of the agonist
32. 2 on coronary vessel tone - Mechanisms of action and therapeutic implications
33. 3H]9-β-[+]fluprostenol): Carboxylic acid of travoprost (AL-6221), a novel FP prostaglandin to study the pharmacology and autoradiographic localization of the FP receptor
34. 3 and FP receptor binding sites in bovine corpus luteum: Characterization and correlation with functional data
35. Arachidonic acid metabolites: Mediators of inflammation in asthma
36. 4-receptor subtype is highly coupled to inhibition of N-formyl-methionyl-leucyl-phenylalanine- stimulated rat neutrophil aggregation
37. In vitro release of prostanoids and leukotrienes from synovial tissue, cartilage, and bone in degenerative joint diseases
38. Characterization of the recombinant human prostanoid DP receptor and identification of L-644,698, a novel selective DP agonist